{"schema_version":"secwatch.filing_event.v1","accession":"0001125345-25-000043","form_type":"8-K","ticker":"MGNX","cik":"0001125345","company_name":"MACROGENICS INC","filed_at":"2025-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.989218+00:00","generated_at":"2026-05-24T09:43:58.377158+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MacroGenics reports FY2024 net loss of $67M; discontinues vobra duo development","bullets":["Net loss of $67.0M ($1.07 diluted EPS) for FY2024 vs. net loss of $9.1M ($0.15) in FY2023.","Total revenue $150.0M, up from $58.7M in FY2023, driven by $85M milestone from Incyte.","Cash, cash equivalents and marketable securities $201.7M at Dec 31, 2024; cash runway extended into H2 2026.","Discontinuing further internal development of vobra duo; seeking partner; Phase 2 TAMARACK rPFS 9.5-10.0 months.","LORIKEET Phase 2 fully enrolled (150 patients); LINNET Phase 2 in ovarian cancer expected mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001125345-25-000043","json":"https://secwatch.observer/filing/0001125345-25-000043.json","markdown":"https://secwatch.observer/filing/0001125345-25-000043.md","text":"https://secwatch.observer/filing/0001125345-25-000043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1125345/000112534525000043/0001125345-25-000043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1125345/000112534525000043/mgnx-20250320.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T09:43:58.377158+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}